

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
 Certification under 37 CFR §1.10 (if applicable)

EL 530 368 225 US  
 Express Mail Label Number

December 17, 1999  
 Date of Deposit

I hereby certify that this Transmittal Letter, enclosed application and any other documents referred to as enclosed herein, are being deposited in an envelope with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR §1.10 on the date indicated above and addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Matthew D. Redlon  
 (Print Name of Person Mailing Application)

(Signature of Person Mailing Application)

**Transmittal of Utility Patent Application**  
**for Filing Under 37 CFR §1.53(b)**

Box Patent Application  
 Assistant Commissioner for Patents  
 Washington, D.C. 20231

Sir:

Transmitted herewith for filing is a utility patent application by inventors: Alberto A. Gabizon, Samuel Zalipsky, Dorit Goren-Rubel, and Aviva T. Horowitz, and entitled:

**METHOD OF ADMINISTERING A COMPOUND TO MULTI-DRUG RESISTANT CELLS**

1. Enclosed are:

- ☒ This Transmittal letter.
- ☒ One stamped, self-addressed postcard for PTO date stamp.
- ☒ Certificate of Express Mail.
- ☒ One utility patent application containing text pages 1-40 and  
☒ 15 Sheets of drawings.
- ☒ Declaration of inventorship (unsigned)
- ☐ Sequence listing printout, diskette, and matching declaration.

2. U.S. Priority

- ☒ This application claims priority to Serial No. 60/113,004 filed December 18, 1998, now pending.
- ☒ Conditional Petition for Extension of Time: An Extension of Time is requested to provide for timely filing if required to establish copendency with the parent after all papers filed herewith have been considered.

3. Foreign Priority

- ☐ Priority of Application No. filed in on is claimed under 35 USC §119.
- ☐ A certified copy of this priority document is enclosed.

12/17/99



JC672 U.S. PTO

JC672 U.S. PTO

09/467413



12/17/99

09/467413.121799

4. Fees

The filing fee has been calculated as shown below:

For:	(Col. 1)	(Col. 2)	Small Entity			Other Than a Small Entity	
	No. Filed	No. Extra	Rate	Fee		Rate	Fee
Basic Fee				\$380.00	or		\$760.00
Total Claims	21 - 20	1	x \$ 9 =	\$	or	1 x \$ 18 =	\$18.00
Independent Claims	4 - 3	1	x \$39 =	\$	or	1 x \$ 78 =	\$78.00
<input type="checkbox"/> Multiple Dependent Claim Presented			+ \$130 =	\$	or	+ \$260 =	\$
* If the difference in Col. 1 is less than zero, enter "0" in Col. 2.							\$856.00
			TOTAL	\$	or	TOTAL	

☒ A check for \$856.00 is enclosed to cover the Filing Fee.

Respectfully submitted,

Date: 12/17/99

*Judy Mohr*  
Judy M. Mohr  
Registration No. 38,563

**Correspondence Address:**

Dehlinger & Associates  
P.O. Box 60850  
Palo Alto, CA 94306  
(650) 324-0880  
Customer No. 22918

**Transmittal of Utility Patent Application for Filing**

Certification Under 37 C.F.R. \$1.10 (if applicable)

EL 530 368 225 US

December 17, 1999

"Express Mail" Label Number

Date of Deposit

I hereby certify that the enclosed application, and any other documents referred to as enclosed herein are being deposited in an envelope with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR \$1.10 on the date indicated above and addressed to the Assistant Commissioner for Patents, Washington, D.C. 20034

Matthew D. Redlon

(Print Name of Person Mailing Application)

(Signature of Person Mailing Application)

**Method of Administering a Compound to  
Multi-Drug Resistant Cells**

5 This application claims the benefit of U.S. Provisional  
Application No. 60/113,004, filed December 18, 1998,  
incorporated herein by reference in its entirety.

**Field of the Invention**

10 The present invention relates to a method for  
administration of a therapeutic compound to multi-drug  
resistant cancer cells.

**Background of the Invention**

15 After heart disease, cancer is the leading cause of death  
in the U.S. With the present methods of treatment, about one-  
third of patients are cured with local measures, surgery or  
radiation therapy, which are generally effective when the tumor  
has not metastasized by the time of treatment. In the remaining  
20 cases, early micrometastasis is a characteristic feature of the  
neoplasm, indicating that a systemic approach, such as  
chemotherapy, is required, often along with surgery or  
radiation.

25 One problem with cancer chemotherapy is drug resistance.  
Some tumor types, e.g., non-small cell lung cancer and colon  
cancer, exhibit primary resistance, i.e., absence of response on  
the first exposure to currently available, conventional  
chemotherapeutic agents. Other tumor types exhibit acquired  
resistance, which develops in a number of drug-sensitive tumor

types. Drug resistant cancer cells demonstrate two types of acquired drug resistance; cells exhibiting single agent resistance or resistance to single class of anti-cancer drugs with the same mechanism of action. The second type involves cells broadly resistant to several or many chemically diverse anti-cancer drugs with different mechanisms of action. This second type of acquired resistance is known as multi-drug resistance.

Multi-drug resistance is also found in some tumor cell types, such as renal and colon tumors, exhibiting primary resistance. That is, in contrast to an acquired multi-drug resistance, certain tumor types are non-responsive to initial treatment with many chemotherapeutic agents.

Multidrug-resistance is often associated with increased expression of a normal gene, the *MDR1* gene, for a cell surface glycoprotein, P-glycoprotein, involved in drug efflux. P-glycoprotein expression correlates with a decrease in intracellular drug accumulation; that is, the P-glycoprotein acts as an energy-dependent pump or transport molecule that removes drugs from the cell, preventing the drug from accumulating in the cell.

P-glycoprotein is normally primarily expressed at epithelial and endothelial surfaces and seems to play a role in absorption and/or secretion. It is an active transporter that pumps hydrophobic drugs out of cells, reducing their cytoplasmic concentration and therefore toxicity. In normal cells, P-glycoprotein functions to eliminate toxic metabolites or xenobiotic compounds from the body (Endicott, J. and Ling, V., *Annu. Rev. Biochem.*, 58:137-171, (1989)).

Cancers which express P-glycoprotein include cancers derived from tissues which normally express the *MDR1* gene, namely cancers of the liver, colon, kidney, pancreas and adrenal. Expression of the gene is also seen during the course of chemotherapy with multidrug-resistant drugs in leukemias, lymphomas, breast and ovarian cancer, and many other cancers. These cancers initially respond to chemotherapy, but when the cancer relapses, the cancer cells frequently express more P-glycoprotein. There are cancers derived from tissues which do

not normally express P-glycoprotein but in which P-glycoprotein expression increases during the development of the cancer. One example is chronic myelogenous leukemia, which when it goes into blast crisis, expresses more P-glycoprotein irrespective of the previous treatment history (Gottesman, M.M. *Cancer Research*, 53:747-754 (1993)).

The *MDR1*-encoded P-glycoprotein pump recognizes and transports many different substances, including most natural product anti-cancer drugs such as doxorubicin, daunorubicin, vinblastine, vincristine, actinomycin D, paclitaxel, teniposide and etoposide (Gottesman, M. et al., *Current Opinion in Genetics and Development*, 6:610-617 (1996)). More generally, the drugs often involved in multidrug-resistance are alkaloids or antibiotics of plant or fungal origin, and they include the vinca alkaloids, anthracyclines, epipodophyllotoxins and dactinomycin. Cross-resistance to alkylating agents such as melphalan, nitrogen mustard, and mitomycin C is occasionally observed (Endicott, J. and Ling, V., *Annu. Rev. Biochem.*, 58:137-171, (1989)).

Clearly, multidrug-resistance in cancer cells limits successful chemotherapy and suggests a poor patient prognosis. One approach that has been described to overcome multi-drug resistance includes coadministration of calcium channel blockers, such as verapamil, which inhibit the drug transport action of P-glycoprotein with the chemotherapeutic agent. This approach has not yet been proven in humans, and other strategies for overcoming multi-drug resistance are needed.

#### Summary of the Invention

Accordingly, it is an object of the invention to provide a composition for administration of an anti-cancer therapeutic agent to a subject suffering from cancer.

It is another object of the invention to provide a composition for administration of an anti-cancer therapeutic agent to multi-drug resistant cells.

In one aspect, the invention includes a composition for administration of a therapeutic agent to a multi-drug resistant cell in a person suffering from cancer. The composition is

composed of a carrier molecule, a folate ligand covalently attached to the carrier, and the therapeutic agent associated with the carrier.

In one embodiment, the carrier is a natural or synthetic polymer. In one preferred example, the polymer is polyethyleneglycol or polypropylene glycol. In another embodiment, the carrier is a macromolecule, such as a peptide or protein.

In a preferred embodiment, the carrier is a liposome having a surface coating of hydrophilic polymer chains to which the folate ligand is attached. The therapeutic agent is entrapped in the liposomes.

In another aspect, the invention includes a liposome composition for administration of a therapeutic compound to a multi-drug resistant cell in a person suffering from cancer. The composition includes liposomes composed of vesicle-forming lipids and including a vesicle forming lipid derivatized with a hydrophilic polymer chain having a free distal end; a folate ligand attached to the free distal end of at least a portion of the hydrophilic polymer chains; and a therapeutic agent entrapped in the liposomes. The composition is effective to achieve accumulation of the therapeutic compound in the cell in an amount sufficient to be cytotoxic.

In one embodiment, the therapeutic agent is a hydrophobic agent capable of partitioning into a liposome lipid bilayer formed by the vesicle-forming lipids. In another embodiment, the therapeutic agent is a neutral drug at physiologic pH and is entrapped in the inner water phase of the liposomes.

In other embodiments, the therapeutic agent is an anthracycline antiobiotic, such as doxorubicin, daunorubicin, epirubicin, idarubicin. In other embodiments, the drug is mitoxantrone or an anthraquinone drug.

The hydrophilic polymer in the liposome composition in one embodiment is selected from polyvinylpyrrolidone, polyvinylmethylether, polymethyloxazoline, polyethyloxazoline, polyhydroxypropyloxazoline, polyhydroxy-propylmethacrylamide, polymethacrylamide, polydimethylacrylamide, polyhydroxy-propylmethacrylate, polyhydroxyethylacrylate,

hydroxymethylcellulose, hydroxyethylcellulose, polyethyleneglycol and polyaspartamide. In a preferred embodiment, the hydrophilic polymer is polyethylene glycol having a molecular weight of at least about 3,500 Daltons. In another preferred embodiment, the hydrophilic polymer is polyethylene glycol having a molecular weight of between 3,500-10,000 Daltons.

In another aspect, the invention includes a liposome composition for administration of a therapeutic compound to the cytoplasm of a cell characterized by increased expression of the MDR1 gene. The liposomes are composed of vesicle-forming lipids and including a vesicle forming lipid derivatized with a hydrophilic polymer chain having a free distal end. A folate ligand is attached to the free distal end of at least a portion of the hydrophilic polymer chains, and a therapeutic agent entrapped in the liposomes.

In yet another aspect, the invention includes, a liposome composition for administration of a therapeutic compound to cells expressing P-glycoprotein, comprising liposomes composed of vesicle-forming lipids and including a vesicle forming lipid derivatized with a hydrophilic polymer chain having a free distal end, and a folate ligand attached to the free distal end of at least a portion of the hydrophilic polymer chains. A therapeutic agent is entrapped in the liposomes.

In still another aspect, the invention includes a liposome composition for administration of a therapeutic compound to a multi-drug resistant cell. The liposomes are composed of vesicle-forming lipids and include a vesicle forming lipid derivatized with a hydrophilic polymer chain having a free distal end; a folate ligand attached to the free distal end of at least a portion of the hydrophilic polymer chains, and a therapeutic agent entrapped in the liposomes.

In still another aspect, the invention includes a method of administering a therapeutic compound to a cell overexpressing P-glycoprotein, by preparing liposomes composed of (i) vesicle-forming lipids and including a vesicle forming lipid derivatized with a hydrophilic polymer chain having a free distal end, (ii) a folate ligand attached to the free

distal end of at least a portion of the hydrophilic polymer chains, and (iii) a therapeutic agent entrapped in the liposomes. The liposomes are then administered to a subject carrying the multi-drug resistant, P-glycoprotein expressing cells.

In yet another aspect, the invention includes a method of administering to a cell a therapeutic compound which in free form does not accumulate in the cell. The method includes preparing a conjugate composed of a carrier molecule, a folate ligand covalently attached to the carrier, and the therapeutic agent associated with the carrier.

In yet another aspect, the invention includes a method of administering to a cell a therapeutic compound which in free form does not accumulate in the cell. The method includes preparing liposomes composed of (i) vesicle-forming lipids and including a vesicle forming lipid derivatized with a hydrophilic polymer chain having a free distal end, (ii) a folate ligand attached to the free distal end of at least a portion of the hydrophilic polymer chains, and (iii) a therapeutic agent entrapped in the liposomes. The liposomes are then administered to a subject to achieve accumulation of the compound in the cell in an amount sufficient for cell cytotoxicity.

In another aspect of the invention, a method of administering a therapeutic compound to a person suffering from a multi-drug resistant neoplastic condition is contemplated. The method includes preparing liposomes composed of (i) vesicle-forming lipids and including a vesicle forming lipid derivatized with a hydrophilic polymer chain having a free distal end, (ii) a folate ligand attached to the free distal end of at least a portion of the hydrophilic polymer chains, and (iii) a therapeutic agent entrapped in the liposomes. The liposomes are then administered to a subject to achieve accumulation of the compound in the cell in an amount sufficient for cell cytotoxicity.

These and other objects and features of the invention will be more fully appreciated when the following detailed description of the invention is read in conjunction with the



accompanying drawings.

### **Brief Description of the Drawings**

Fig. 1 is a synthetic reaction scheme for the preparation of a folic acid-PEG-DSPE conjugate, showing the structure of the  $\gamma$ -carboxyl-linked conjugate;

Fig. 2 shows the results of a competitive binding study to determine binding of radio-labeled folic acid at a concentration of 0.1  $\mu$ M to cellular folate receptor in murine lung carcinoma cell with a high density of folate receptor (M109R-HiFR) in the presence of the following competitors: free folate (open circles), free PEG<sub>2000</sub> (closed squares) or a PEG-folate conjugate (closed triangles) at varying concentrations;

Figs. 3A-3F are schematic illustrations of the liposome compositions prepared in support of the present invention;

Figs. 4A-4B shows binding of various folic acid bearing liposomes and control liposomes (no folic acid ligand) to murine lung carcinoma cells with high (M109-HiFR) and low (M109-LoFR) density of folate receptor (Fig. 4A) and to human epidermal carcinoma cells having a high density of folate receptor (KB-HiFR) and a low density of folate receptor (KB-LoFR) (Fig. 4B);

Figs. 5A-5D are confocal microscopic images of M109-HiFR cells incubated with rhodamine-labeled, folate targeted liposomes (Figs. 5A-5B) and with rhodamine-labeled, folate targeted liposomes having additional PEG chains (Figs. 5C-5D);

Figs. 6A-6B are confocal microscopic images of M109-HiFR cells incubated with rhodamine-folic acid-PEG<sub>2000</sub> liposomes (HSPC/Chol/DSPE-PEG-Folate/DPPE-rhodamine (98.9:70:1.0:0.1)) for 30 minutes (Fig. 6A) and for 50 minutes (Fig. 6B);

Figs. 7A-7B are confocal microscopic images of M109-HiFR cells incubated with rhodamine-folic acid-PEG<sub>2000</sub> liposomes and with 2 mM free folate incubated for 4 hours (Fig. 7A) and for 19 hours (Fig. 7B);

Figs. 8A-8B are confocal microscopic images of M109-HiFR cells (Fig. 8A) and M019-HiFR cells treated with phosphatidylinositol-phospholipase C (Fig. 8B)) and incubated

with rhodamine-folic acid-PEG<sub>2000</sub> liposomes for 1 hour;

Figs. 9A-9F are images of M109R-HiFR cells (a subline of M109 cells selected for multi-drug resistance) incubated with free doxorubicin for 7 minutes (Fig. 9A) and for 30 minutes (Fig. 9B); with doxorubicin-loaded, folate-targeted liposomes for 20 minutes (Fig. 9C), 60 minutes (Fig. 9D) and for 90 minutes (Fig. 9E); and with non-folate-targeted liposomes coated with mPEG-DSPE (known commercially as DOXIL) for 4 hours (Fig. 9F);

Figs. 10A-10D are images of M109R-HiFR cells incubated for 1 hour with free doxorubicin (Fig. 10A) or with folate-targeted liposomes containing doxorubicin (Fig. 10B) and for 24 hours in drug free medium after 1 hour of incubation with free doxorubicin (Fig. 10C) or with folate-targeted liposomes containing doxorubicin (Fig. 10D);

Figs. 11A-11B are results from the flow cytometry assay for M109R-HiFR cells exposed to free doxorubicin (Fig. 11A) and to folate-targeted liposomes carrying doxorubicin (Fig. 11B) in the presence or absence of verapamil, a P-glycoprotein blocker;

Fig. 12 is a plot showing the kinetic of doxorubicin uptake by M109R-HiFR cells exposed to doxorubicin entrapped in folate-targeted liposomes at drug-to-lipid ratios of 137.6  $\mu\text{g}/\mu\text{mol}$  (closed circles) and 11.3  $\mu\text{g}/\mu\text{mol}$  (open circles);

Fig. 13 is a bar graph showing the accumulation of doxorubicin in M109R-HiFR cells after exposure to free doxorubicin and doxorubicin entrapped in folate-targeted liposomes for 1 hour and for 4 hours, where the accumulation was determined for the cell nuclei and cytosol;

Figs. 14A-14B show cytotoxicity results for M109-HiFR (Fig. 14A) and M109R-HiFR (Fig. 14B) cells when exposed to doxorubicin in free form (closed circles) or in folate-targeted liposome-entrapped form (closed triangles) or in non-folate-targeted liposome-entrapped form (closed squares);

Figs. 15A shows the time course of mean footpad thickness, in mm, after injection of tumor cells into the footpad of mice, where the tumor cells were treated *in vitro* prior to injection

with free doxorubicin (closed circles), liposome-entrapped doxorubicin (open squares) or with folate-targeted liposomes (closed triangles). The control mice received untreated tumor cells (open circles);

Fig. 15B shows the mean footpad tumor weight, in grams, on day 34 of the test animals of Fig. 15A, where the footpad tumor weight is taken as the weight of the footpad on day 34 minus the average footpad weight of a healthy mouse; and

Fig. 16 is a plot showing the number of palpable tumors after subcutaneous injection of untreated (control, open circles) or *in vitro* treated tumor cells with free doxorubicin (closed circles), doxorubicin entrapped in non-targeted liposomes (open squares) and doxorubicin entrapped in folate-targeted liposomes (closed triangles).

#### **Detailed Description of the Invention**

The invention, in one aspect, is directed to a composition for administration of a therapeutic agent to a multi-drug resistant cell. In practice, the composition provides for administration of a therapeutic agent to a person suffering from cancer, and in particular from a cancer which expresses P-glycoprotein on the cancer cell surfaces. As noted above, certain cancers, such as renal cancer and colon cancer exhibit primary resistance, as opposed to secondary or refractory resistance, to many chemotherapeutic agents. The composition and method of the invention provides for treatment of these cancers, as well as those cancers that are refractory, e.g. as in those cancer that develop multi-drug resistance where the cancer is initially responsive to a therapeutic agent or group of agents but progresses to a state that is no longer responsive or successfully treatable by the agent(s).

In one aspect, the invention includes a composition composed of a carrier, a folate targeting ligand, and the drug to be administered. The folate ligand is covalently attached to the carrier, and the drug is associated with the carrier. By associated, it is meant, that the drug is covalently or electrostatically attached, or is entrapped or encapsulated with the carrier. As will be described below, the composition

is effective to achieve accumulation of the drug in multi-drug resistant cells, i.e., cells expressing the P-glycoprotein which acts as an efflux pump to prevent accumulation of drug in the cell, in an amount sufficient to be cytotoxic to the cell. By "cytotoxic" it is meant that the amount of drug accumulated in the cells is sufficient to prevent normal cell functioning and, preferably, to cause cell death.

In one embodiment of the invention, the carrier is a natural or synthetic polymer. The polymer in this embodiment can be any biocompatible polymer, that is a polymer which is nontoxic, biologically inert, nonallergenic and nonirritating to body tissue, and that maintains its physical and chemical integrity for a time sufficient to achieve a desired biodistribution. Exemplary synthetic polymers include polyglycols, polylactic acids, polyglycolid acid and celluloses. Attached to the carrier, either at an end or along the carrier itself or attached to the surface of a microsphere prepared from the carrier, is a folate ligand, which will be described below. The drug to be administered is also attached to the carrier or is in some way associated with the carrier so that it moves with the carrier and the targeting folate ligand. As will be described below, the folate effectively targets the conjugate to a multi-drug resistant cell for delivery and accumulation of the drug in the cell.

In another embodiment, the carrier is a protein or peptide having moieties capable of association with the drug ligand. The protein or peptide carrier is one having sufficient chemical and physical integrity following administration of the composition to achieve a desired biodistribution. Exemplary materials include collagen, hyaluronic acid, polysaccharides, albumin and gelatin.

In a preferred embodiment of the invention, the carrier is a liposome. In studies performed in support of the invention, folate-targeted liposomes were prepared and the general concept was demonstrated using the carrier liposomes. It will be appreciated, however, that the useful teaching from the liposome studies is applicable to a number of carriers, as will be apparent from the studies described below.

I. Preparation of Folate-Receptor Targeted LiposomesA. Synthesis and Characterization of mPEG-folic acid and folic acid-PEG-DSPE

Conjugates composed of folate, polyethylene glycol (PEG) and distearoyl phosphatidyl ethanolamine (DSPE) (folic acid-PEG-DSPE) were prepared as shown in Fig. 1, via a dicyclohexylcarbodiimide - mediated coupling of folic acid to H<sub>2</sub>N-PEG-DSPE. As described in Example 1A, the starting amino-PEG lipids were synthesized from PEG having molecular weights 2000 Daltons and 3350 Daltons according to previously described methods (Zalipsky, S. *et al.*, *FEBS Lett.* 353:71-74 (1994)). Conjugates of folic acid and methoxy-PEG, *e.g.*, conjugates without the phospholipid moiety, were prepared using the same coupling method. The structures of the purified conjugates were corroborated by <sup>1</sup>H-NMR, MALDI-TOFMS and UV spectroscopy, as set forth in Examples 1B-1C. Carbodiimide-activated folic acid can couple with H<sub>2</sub>N-PEG-DSPE via either  $\alpha$  or  $\gamma$ -carboxyl groups of its glutamate residue. The  $\gamma$ -conjugate binds to the folate receptor, whereas the  $\alpha$ -conjugate does not, therefore the relative amounts of each conjugate were determined by a method using carboxypeptidase G (CPG). As described in Example 1E, a method using carboxypeptidase G (CPG) was used, since it is known that  $\alpha$ -conjugates are inert to the enzyme while the  $\gamma$ -conjugates are subject to pterooate-glutamate cleavage at an appreciable rate (Wang, S. *et al.*, *Bioconjugate Chem.*, 7:56-62 (1996); Fan, J., *et al.*, *Biochemistry*, 30:4573-4580 (1991); Levy C. and Goldman P., *Biol Chem.*, 242:2933-2938 (1967)). The enzymatic cleavage was followed by disappearance of the conjugate peak by HPLC. This reaction proceeded up to 80% conversion despite prolonged incubation times and multiple additions of the enzyme, indicating that folic acid-PEG-DSPE contained 80%  $\gamma$ -carboxy linked and the remaining 20% were  $\alpha$ -linked conjugates. The same approach was used to determine that 90% of mPEG-folic acid was linked through the  $\gamma$ -carboxyl group.

The conjugates were characterized by binding studies, as will now be described. As set forth in Example 2, three of the

cell lines used, the murine lung carcinoma (M109), a multidrug-resistant subline of M109 (M109R) and human nasopharyngeal epidermal carcinoma (KB) were induced to upregulate their folic acid receptors by consecutive passages in folic acid-depleted medium (3 nM folic acid). This resulted in three cell sublines referred to as "high folate receptor" (HiFR) with 20-80 fold increase in folic acid-binding capacity over the parental cell lines, which are referred to herein as "low folate receptor" (LoFR).

These cell lines and their capacity to bind folic acid were determined as set forth in Example 2B, by incubating the cells for 30 minutes with folic acid at 37°C. Two of the cell lines, the M109-LoFR and KB-LoFR cells, were also assayed for folic acid binding after 24 hours of incubation in folic acid-depleted medium. The folate binding to normal human fibroblasts in early passage and to a human melanoma line A375 was also determined, to obtain a spectrum of different cell lines with a broad range of receptor expression levels.

The results are summarized in Table 1.

**Table 1**

CELL LINE	CELL LINE ABBREVIATION	FOLIC ACID BINDING <sup>a</sup> (FEMTOMOLES/10 <sup>4</sup> CELLS)
Murine Lung Carcinoma Low Folate Receptor	M109-LoFR	20±6
Murine Lung Carcinoma Low Folate Receptor	M109-LoFR <sup>b</sup>	25±13
Multidrug-resistant murine lung carcinoma Low Folate Receptor	M109R-LoFR	27±10
Murine Lung Carcinoma High Folate Receptor	M109R-HiFR	678±255
Multidrug-resistant High Folate Receptor	M109R-HiFR	2179±430
Nasopharyngeal epidermal carcinoma Low Folate Receptor	KB-LoFR <sup>b</sup>	6725±323
Nasopharyngeal epidermal carcinoma High Folate Receptor	KB-HiFR	9730±79
Human Melanoma line A375	A375	168±33
Normal Human Fibroblasts	NHF	45±3

<sup>a</sup> Incubation time, 30 min, at 37°C

<sup>b</sup> After culture in folic acid-depleted medium for 24 h.

When the line with the lowest (M109-LoFR) and highest (KB-HiFR) amount of receptors are compared, differences in folic acid binding capacity up to 485-fold were observed. Also as seen in Table 1, for the cell lines incubated for 24 hours in folic acid-depleted medium, M109-LoFR did not upregulate the amount of folic acid binding. In contrast, KB-LoFR showed a 15-fold increase in folic acid binding indicating rapid upregulation of receptor expression.

In further studies to characterize the binding of folic acid with the folate receptor-overexpressing M109-HiFR cell line, the following observations were made:

i) binding is directly proportional to cell number in the range of  $10^3$  to  $1.5 \times 10^6$  cells per plate;

ii) monolayer cultures of M109R-HiFR cells pretreated with phosphatidylinositol-phospholipase C (PI-PLC) (see Example 2B) lose 99% of their folic acid receptors, as shown by binding assay with folic acid, indicating that the overexpressed folate receptor is bound to the cell membrane by a glycopospholipid anchor. In contrast, trypsin treatment does not damage the folate receptor, as indicated by (a) radiolabeled folic acid binds to a similar extent to plated cells and to suspension cells after trypsinization, and (b) cell-bound radiolabeled folic acid is almost fully recovered (91±11%) after trypsinization; and

iii) Only 2±1% of folic acid remains bound to M109R-HiFR cell monolayers following acid wash (pH 3), indicating that the binding of folic acid to the overexpressed receptors is pH-sensitive. To prevent internalization, the folic acid binding assay took place at ~1°C for 30 min. When M109R-HiFR cells are incubated for 4 hours at 37°C with radiolabeled folic acid, and then submitted to acid wash, 30 to 40% of the ligand is retained by cells. This is most likely the fraction of folic acid ligand that is internalized by cells, thus avoiding the pH-induced dissociation from the receptor.

As described in Example 2B, a competition binding study was performed with folic acid, mPEG-folic acid, and free PEG. In this study, M109R-HiFR cells were exposed to a constant amount of radiolabeled folic acid at a concentration of 0.1 µM.

"Cold" folic acid, mPEG-folic acid, and free PEG were added to the M109R-HiFR cells at concentrations varying from 0.1 to 100  $\mu$ M. The PEG<sub>2000</sub> and the mPEG<sub>2000</sub>-folic acid conjugate were freely water-soluble, not lipid linked, compounds. The latter derivative can be viewed as a monovalent version of folic acid-PEG<sub>2000</sub>-liposome as will be discussed below.

The results of the competitive binding assay are shown in Fig. 2 as percentage of binding against concentration in  $\mu$ M of each of the competitors, free folic acid (open circles), PEG-folic acid (closed triangles) and PEG (closed squares). As seen, mPEG-folic acid was less effective than free folic acid in competing with radiolabeled folic acid for binding to the folate receptors, suggesting that the attachment of PEG to the vitamin molecule diminishes by 5 to 10-fold the ability of folic acid to bind to the receptor. Free PEG exhibited no cell binding, showing no competition with folic acid binding.

#### B. Liposome Preparation

Six liposome formulations were prepared according to the procedures set forth in Example 3. The six liposomal compositions are summarized in Table 2.

**Table 2**

Components	Molar Ratio of Components	Abbreviation
HSPC:Chol:folic acid-PEG <sub>2000</sub> -DSPE	99.5 : 70 : 0.5	folic acid-PEG <sub>2000</sub>
HSPC:Chol:folic acid-PEG <sub>3350</sub> -DSPE	99.5 : 70 : 0.5	folic acid-PEG <sub>3350</sub>
HSPC:Chol:mPEG <sub>2000</sub> -DSPE	99.5 : 70 : 0.5	Low mPEG <sub>2000</sub>
HSPC:Chol:folic acid-PEG <sub>2000</sub> -DSPE:mPEG-DSPE	92.5 : 70 : 0.5 : 7	folic acid-PEG <sub>2000</sub> /mPEG
HSPC:Chol:folic acid-PEG <sub>3350</sub> -DSPE:mPEG-DSPE	92.5 : 70 : 0.5 : 7	folic acid-PEG <sub>3350</sub> /mPEG
HSPC:Chol:mPEG <sub>2000</sub> -DSPE	92.5 : 70 : 7.5	High mPEG <sub>2000</sub>

As can be seen in Table 2, all of the formulations contained HSPC, Chol, and DSPE, thus, they are referred to herein according to folic acid-PEG/mPEG content, as noted in



the right-hand column of the table. Figs. 3A-3F schematically illustrate the liposomal formulations. Four folate-targeted liposome formulations were prepared (Figs. 3B, 3C, 3E, 3F); two formulations included a folic-acid-PEG conjugate prepared with PEG molecular weight of either 2000 Daltons (Fig. 3B; folic-acid-PEG<sub>2000</sub>) or 3500 Daltons (Fig. 3C; folic-acid-PEG<sub>3350</sub>) and two formulations that included the folic-acid-PEG conjugate in addition to an mPEG-DSPE conjugate prepared with mPEG of molecular weight 2000 Daltons (Fig. 3E, folic acid-PEG<sub>2000</sub>/mPEG and Fig. 3F, folic-acid-PEG<sub>3350</sub>/mPEG). In all four formulations the folic acid-PEG- conjugate derived from PEG of molecular weight 2000 or 3350 Daltons was included at a molar fraction of 0.5% of total liposomal phospholipid. The two control formulations contained no folate (Figs. 3A and 3D) and differed in the mole fraction of mPEG<sub>2000</sub>-DPSE included (0.5% and 7.5%, respectively).

In the studies in support of the invention, discussed below, it was found that the control liposome formulation, that is the non-targeted high-mPEG and low-mPEG formulations, behaved similarly *in vitro*, therefore, data are presented only for the high-mPEG liposomes.

### C. In vitro Binding Studies

The binding of radiolabeled folic acid-targeted liposomes and the control, non-targeted liposomes was assayed on monolayer cultures of the multi-drug resistant cell lines with both high and low folate receptors level, M109R-HiFR and M109R-LoFR cells, at 37 °C for 24 hours, as described in Example 2B.

The results are shown in Fig. 4A where the amount of liposomes bound to trypsin-released cells, expressed as picomoles phospholipid per million cells, is shown for each of the liposome formulations. As seen in the figure, binding of the non-targeted, conventional mPEG liposomes to the multidrug-resistant cells was very low for both high and low folic acid receptor levels. The targeted formulation with the highest binding efficiency was the liposomes having the folic acid-PEG<sub>3350</sub> conjugate, which achieved a 26-fold increase in binding over the non-targeted liposomes. Accordingly, in one

embodiment of the invention, the composition includes a liposomal carrier having PEG polymer chains with a molecular weight of at least about 3,500 Daltons, with a preferred range between 2,500-10,000 Daltons and a more preferred range between 3,500-10,000 Daltons. In the embodiment, the composition is effective to achieve at least a 10-fold, more preferably a 20-fold, and most preferably a 25-fold increase in binding compared to a composition having PEG chains with a molecular weight of less than about 2,500 Daltons, and specifically a molecular weight of 2,000 Daltons.

With continuing reference to Fig. 4A, addition of mPEG to the formulation or shortening of the PEG tether from 3350 to 2000 reduced the binding substantially. Binding was greater for M109R-HiFR cells than for M109R-LoFR cells for all of the liposome formulations. Interestingly, the highest affinity liposome formulation, e.g., liposomes having the folic acid-PEG<sub>3500</sub>, showed the lowest relative increase of binding (~30%) when the LoFR and HiFR cells were compared.

Fig. 4B is a plot similar to Fig. 4A, except that the study was performed with the KB cell line. As seen in the figures, the addition of mPEG to the liposomes reduced the efficiency of binding. In the absence of mPEG, a longer PEG spacer (3350 Daltons) increased only slightly the efficiency of binding to KB cells. The differences between KB-HiFR and KB-LoFR were for some of the liposome compositions smaller than as seen for the M109R cells. This may be related to the rapid up-regulation of folate receptors in KB cells during the 24 hour incubation period, as discussed above with reference to Table 1.

To study if the cell-associated liposomes were cell-surface bound or internalized into cells, an acid wash with saline, pH 3, was performed at the end of the binding assay. The results, which are shown in the last column of Table 3, indicate that about 22% of folic acid-PEG<sub>3350</sub> and 32% of folic acid-PEG<sub>3350</sub>/mPEG liposomes were removed by the acid wash, which indicates that more than 2/3 of the cell-associated liposomes have been internalized by M109R-HiFR cells. Also shown in Table 3 are competition studies with 1 mM folic acid (~700-fold

excess over the concentration of liposome-bound folic acid) added to the liposome/cell mixture, either at the beginning or at the end of the incubation of the liposomes with the cells. As seen in the table, folic acid added at the beginning of the incubation period of the targeted FA-PEG<sub>3350</sub> liposomes with the M109R-HiFR cells only partially inhibits (46%) liposome binding. Addition of the folic acid at the end of the 24 hour liposome/cell incubation, results in no significant displacement of folic acid-bearing liposomes from the cells, despite the fact that, according to acid wash experiments, approximately 20-30% of the liposomes were still bound to the cell surface. These studies demonstrate the greater binding avidity of folic acid-PEG liposomes over free folic acid for the cellular folate receptor, which is in contrast to 5-10 fold less efficient binding of the monovalent analog, mPEG-folic acid (Table 1). The stronger binding of folic acid-targeted liposomes is related to the multivalent presentation of folic acid residues on the liposomal platform.

**Table 3**

ADDITIONAL TREATMENT	1mM FA AT TIME 0 (A)		1mM FA AT TIME 24 h (B)		ACID WASH AT 24h (C)	
Liposome Composition	FA-PEG	FA-PEG / mPEG	FA-PEG	FA-PEG / mPEG	FA-PEG	FA-PEG / mPEG
% inhibition	46±8	86±6	2±3	8±4	22±2	32±5

- (a) M109R-HiFR cells were incubated for 24 h with 300 nmol/mL FA-PEG<sub>3350</sub>-  
 or FA-PEG<sub>3350</sub>/mPEG-coated liposomes in the presence or absence of free FA  
 (b) or FA added for 2 h after 24 h incubation with liposomes  
 (c) or cells washed with acid saline (pH 3)

As noted above, these studies suggested that liposome formulations which include mPEG-DSPE in addition to the PEG chains having the attached folate ligand, e.g., the folic acid-PEG<sub>2000</sub>/mPEG and folic acid-PEG<sub>3350</sub>/mPEG formulations, interfere with binding to the target cells. This suggestion was further examined by exposing cells to rhodamine-labeled liposomes, prepared as described in Example 4, and viewing the cells by

confocal microscopy. M109-HiFR cells were incubated to rhodamine-folic acid-PEG<sub>2000</sub> liposomes (HSPC/Chol/DSPE-PEG-Folate/DPPE-rhodamine (98.9:70:1.0:0.1)) or with rhodamine-folic acid-PEG<sub>2000</sub>/mPEG<sub>2000</sub> liposomes (HSPC/Chol/mPEG-DSPE/DSPE-PEG-Folate/DPPE-rhodamine (91.9:70:7:1.0:0.1)) for 7 hours and examined by confocal microscopy. The results are shown in Figs. 5A-5B and Figs. 5C-5D for the rhodamine-folic acid-PEG<sub>2000</sub> liposomes and the rhodamine-folic acid-PEG<sub>2000</sub>/mPEG<sub>2000</sub>, respectively. As seen in Figs. 5A-5B, the cytoplasm of M109-HiFR cells exposed to folate-targeted liposomes with no additional PEG chains are loaded with rhodamine-labeled liposomes. In contrast, as seen in Figs. 5C-5D, liposomes with the additional mPEG have poor binding to the cells, as evidenced by the faint signal of rhodamine associated with the cell surface and the failure of the liposomes to internalize into the cells. These results confirm that the folate ligand is able to mediate binding and internalization of folate-targeted liposomes to cells with over-expressed folate receptors and that the additional PEG chains appear to interfere with these processes.

In another study performed in support of the invention, M109-HiFR cells were incubated with rhodamine-folic acid-PEG<sub>2000</sub> liposomes (HSPC/Chol/DSPE-PEG-Folate/DPPE-rhodamine (98.9:70:1.0:0.1)) in folate-free medium. After 30 minutes and after 50 minutes of incubation, the cells were visualized with confocal microscopy and the images are shown in Figs. 6A-6B. As seen in Fig. 6A, after 30 minutes of incubation, the folate-targeted liposomes are associated with the M109-HiFR cells, and after 50 minutes, as seen in Fig. 6B, some liposomes are internalized and accumulate in the cell cytosol. In the same study, some cells were also exposed to free folic acid at a concentration of 2 mM, which was equivalent to about a 1000 times the concentration of liposomal-bound folate. This competitive binding study was conducted to verify interaction between the folate ligand and the folate receptor. After 30 minutes and 50 minutes of incubation, the cells were visualized and no liposome binding was observed (Fig. 6), suggesting that the free folate was able to competitively block binding of the

folate-targeted liposomes to the cellular folate receptor. After longer exposure times of 4 hours and 19 hours folate-targeted liposome binding to the M109-HiFR cells was no longer blocked by the free, soluble folate and the cell cytoplasm was stained with rhodamine fluorescence, as seen in Figs. 7A-7B.

Without being bound to any particular theory, the results of the competitive binding study may be due to the fact that affinity of binding is higher for liposomal folate than for free folate, in view of the multivalency of the liposomes.

However, equilibrium for the folate liposomes is reached after a longer period of time, particularly in view of the large excess (1000 fold) of free folate and the more rapid mobility of small molecules as compared to nanoparticles (liposomes).

Further evidence of the involvement of the folate receptor with the folate-targeted liposomes with M109-HiFR cells is provided by the studies conducted with cells pretreated with phosphatidylinositol-phospholipase C (PI-PLC) (Example 2B) to destroy the folate receptor. Exposure of PI-PLC pretreated M109-HiFR cells to rhodamine-labeled, folate-targeted liposomes for 1 hour at 4°C resulted in no detectable binding as seen in the image of Fig. 8A. The same liposomes, however, were bound by non-PI-PLC-treated cells, as seen in the image of Fig. 8B. At 4°C binding to the receptor occurs but internalization and recycling of receptor the to cell surface do not occur (Kamen B.A. and Capdevila A., *Proc. Natl. Acad. Sci. USA.*, **83**:5983-5987 (1986)). The inability of folate-targeted liposomes to associate to the enzyme-treated M109 HiFR cells provides evidence that the glycopospholipid-anchored folate receptor is involved in liposome-cell association.

#### 1. In vitro Binding Studies Using Doxorubicin Loaded Liposomes

As described in Example 5, folate-targeted liposomes containing doxorubicin were prepared and incubated with M109R-HiFR cells. For comparison, M109R-HiFR cells were also incubated with free doxorubicin or with liposomes containing doxorubicin but with no folate targeting ligand. The movement of the doxorubicin molecule was tracked using fluorescence and

the results are shown in Figs. 9A-9F.

Figs. 9A-9B are images for cells exposed to free doxorubicin for 7 minutes (Fig. 9A) and for 30 minutes (Fig. 9B). The influx of free doxorubicin through the cell membranes was very rapid as indicated by the bright cytoplasmic staining in Fig. 9A. As can be seen in Fig. 9B, the free drug was already located in the nucleus within 30 minutes.

The kinetics of cell interaction with doxorubicin-loaded, folate-targeted liposomes was considerably different from that with free doxorubicin. As seen in Figs. 9C-9E, liposome attachment to the cell membrane was observed within approximately 20 minutes (Fig. 9C). By 60 minutes, internalization has taken place and liposomal doxorubicin was detected in the cytosol and, in a few cells, the drug began to appear in the nucleus (Fig. 9D). After 90 minutes, doxorubicin delivered from folate-targeted liposomes has reached the nucleus in most of the cells while the cytoplasmic drug fluorescence has disappeared (Fig. 9E). In contrast to folate-targeted liposomes, a formulation of non-targeted liposomes coated with mPEG-DSPE (known commercially as DOXIL) showed no association with the M109R-HiFR cells, as seen in Fig. 9F, even after 4 hours of incubation. This study was repeated with fresh and fixed cells with essentially similar results.

In another study, the ability of the M109R-HiFR cells to retain doxorubicin after treatment for 1 hour with either free doxorubicin or with doxorubicin-loaded folate-targeted liposomes, followed by incubation in drug-free medium for 24 hours was examined. As seen in Figs. 10A-10D, the cell nuclei are stained by doxorubicin fluorescence after 1 hour of incubation with both the free drug (Fig. 10A) and with the liposome-entrapped drug (Fig. 10B). However, after 24 hours the fluorescence has almost completely waned in the cells treated with the free drug, as seen in Fig. 10C. The fluorescence in the cells treated with the liposomes is still clearly detectable, as seen in Fig. 10D. These results show that liposomal drug is retained in the drug resistant cells better than free drug.

## 2. Further Evidence of Drug Accumulation in MDR Cells

As described in Example 6, studies were performed to show that intracellular delivery of doxorubicin via the folate receptor pathway in the form of folate-targeted doxorubicin-carrying liposomes overcomes the P-170 glycoprotein efflux pump.

In one study, the activity of the P-170 glycoprotein pump in M109R-HiFR cells was examined by flow cytometry using a rhodamine efflux assay and was found to be sensitive to verapamil blockade (data not shown). Using this technique, the efflux of doxorubicin intracellularly delivered in free form and in folate-targeted liposome-entrapped form was examined. Monolayers of M109R-HiFR cells were exposed to doxorubicin in free form or in liposome-entrapped form for 1 hour in the presence of verapamil. The cells were rinsed and incubated again in 10  $\mu$ mol verapamil for 2 hours. The cells were then analyzed for cellular doxorubicin content using fluorescence and by flow cytometry.

The results from flow cytometry are shown in Figs. 11A-11B for the cells treated with free doxorubicin (Fig. 11A) and with liposome-entrapped doxorubicin (Fig. 11B). As seen in Fig. 11A, the curve shift indicates a clear increase of cell fluorescence in M109R-HiFR cells after exposure to free doxorubicin in presence of verapamil. In contrast, the cellular level of fluorescence in M109R-HiFR cells upon exposure to the folate-targeted liposomal drug appears unchanged in the presence or absence of verapamil (Fig. 11B). These observations were confirmed by quantitative fluorometry of doxorubicin from cell extracts as summarized in Table 4.

Table 4

Exposure Time (minutes)	Intracellular Doxorubicin Content ng/1.5 x 10 <sup>6</sup> cells			
	Free Doxorubicin	Free Doxorubicin + verapamil	Targeted, liposomal Doxorubicin	Targeted, liposomal Doxorubicin + verapamil
30	24	89.8	155.7	151.5
60	42.5	166.5	198.5	192.2

As seen in the table, the presence of verapamil had no effect on the amount of drug accumulating in the drug-resistant cells when delivered via folate-targeted liposomes. In contrast, cell retention of doxorubicin administered in free form was ~4.5 fold higher in the presence of verapamil. Drug retention is approximately 4-6 fold higher when administered from folate-targeted liposomes. These results indicate that free doxorubicin diffusing into the cells is pumped out by P-170 glycoprotein pump action, while doxorubicin entry via the folate receptor pathway avoids the P-glycoprotein efflux machinery.

In an additional study to confirm enhancement of drug delivery to cells via folate-targeted liposomes, drug-resistance (M109R) cells and drug-sensitive (M109) cells were exposed to  $0.2 \times 10^{-5}$  M and  $0.5 \times 10^{-6}$  M doxorubicin, respectively. The doxorubicin was administered to the cells in free form and entrapped in folate-targeted liposomes. The cell-associated drug was measured after 1 hour and 4 hours of exposure to doxorubicin. The results are shown in Table 5.

**Table 5**  
**Percent Doxorubicin in Cells After Administration and Amount of Doxorubicin in Cells**

Exposure Time (hours)	Percent doxorubicin administered remaining in cells <sup>1</sup> and intracellular doxorubicin (ng/ $1.5 \times 10^6$ cells) <sup>2</sup>			
	Drug-Resistant Cells		Drug Sensitive Cells	
	Free Doxorubicin	Targeted, liposomal Doxorubicin	Free Doxorubicin	Targeted, liposomal Doxorubicin
1	<b>5.5</b> (159)	<b>13.2</b> (385)	<b>8.6</b> (25)	<b>12.7</b> (37)
4	<b>4.2</b> (122)	<b>20.5</b> (595)	<b>12.4</b> (36.1)	<b>22</b> (64)

<sup>1</sup> values in bold are percent of doxorubicin administered remaining in cell

<sup>2</sup> values in parenthesis are ng of doxorubicin in the cells

The data in Table 5 shows that drug-resistant cells exposed to free doxorubicin pump out the drug, even in the presence of excess drug in the extracellular medium bathing the drug. In contrast, drug resistant cells exposed to doxorubicin in the form of folate-targeted liposomes accumulate doxorubicin



in the cells. As expected, the drug sensitive cells are able to accumulate doxorubicin in both free form and in liposome-entrapped form. These data show that while drug-resistant cells exposed to free doxorubicin effectively pump out the drug, drug delivery and accumulation in the cells effectively occurs when delivered via the folate pathway.

The dependence of drug uptake and accumulation in drug-resistant cells on the folate pathway is further supported by the study presented in Fig. 12. In this study, two formulations of folate-targeted liposomes having entrapped doxorubicin were prepared. One formulation had a drug-to-lipid ratio of 137.6  $\mu\text{g}/\mu\text{mol}$  (closed circles in Fig. 12) and the other had a drug-to-lipid ratio of 11.3  $\mu\text{g}/\mu\text{mol}$  (open circles).

M109R-HiFR cells were incubated with the liposome formulations and the uptake of drug into the cell was monitored as a function of time. As seen in Fig. 12, the cellular accumulation of doxorubicin was consistently higher by a factor of ~10 for the liposomes having the 10-fold higher drug-to-lipid ratio. The steady accumulation of targeted liposomal drug by tumor cells during the 24-hour incubation period, without evidence of efflux and without plateau level, is also apparent from the curves in Fig. 12.

In another study, the quantitative amount of doxorubicin accumulated in the cell nucleus and the cell cytosol was determined via cell fractionation. M109R-HiFR cells were incubated with free doxorubicin or with doxorubicin entrapped in folate-targeted liposomes for 1 hour and for 4 hours. Accumulation of doxorubicin in the cell nuclei and cytosol was measured fluorimetrically after separation of the cell nuclei from the cytosol, as set forth in Example 7. The results are shown in Fig. 13, where as seen, after 1 hour of incubation, most of the drug is found in the nuclear fraction with both free doxorubicin (DOX) and targeted-liposomal doxorubicin. After 4 hours of incubation, the nuclear drug concentration obtained with targeted liposomal doxorubicin clearly surpasses the concentration obtained with free doxorubicin. HPLC analysis of drug accumulated in cells exposed to folate-targeted liposomes shows that the accumulated drug is intact

drug (data not shown), indicating that this route of delivery does not lead to drug degradation. Also, no significant amounts of metabolites were detected after 1 to 4 hours exposure of tumor cells to either free doxorubicin or folate-targeted liposomal doxorubicin.

### 3. Cytotoxicity

The cytotoxicity of doxorubicin delivered to M109-HiFR cells in free form and in folate-targeted, liposome-entrapped form was compared, as described in Example 8. Briefly, M109-HiFR cells were exposed to free or liposomal doxorubicin for 1 hour, then washed and further incubated for 5 days (120 hours) in fresh medium. As seen in Fig. 14A, the growth inhibition curve of doxorubicin in folate-targeted liposomes (closed triangles) is similar to that for doxorubicin administered in free form (closed circles), and considerably higher to that of doxorubicin when administered in the form of conventional, non-targeted liposomes (closed squares).

A similar cytotoxicity assay was done using the multi-drug resistant subline, M109R-HiFR and the results are shown in Fig. 14B. A clear enhancement of cytotoxicity was obtained when the drug was administered to the cells via folate-targeted liposomes (closed triangles) when compared to drug administered from conventional, non-targeted liposomes (closed squares).

## II. In vivo Characterization of the Composition

To examine the biological activity of drug delivered by the folate-pathway from folate-targeted liposomes in another model, M109R-HiFR cells *in vitro* were exposed to a test drug. These cells were inoculated into mice footpads. In this way, the growth of cells was tracked along a much longer time span than in *in vitro* experiments, and the influence of *in vivo* micro-environmental factors is brought into play. However, unlike therapeutic experiments, this type of *in vivo* adoptive assay is unaffected by pharmacokinetic and biodistribution factors which complicate the interpretation of results.

Accordingly, tumor cells *in vitro* were incubated with free doxorubicin or with liposome-entrapped, non-folate-targeted

doxorubicin (DOXIL®) or with folate-targeted, liposome-entrapped doxorubicin in accord with the invention. As described in Example 9, the tumor cells were incubated in the presence of the selected formulation for 1 hour and then  $1 \times 10^6$  cells were  
5 injected into the footpad of a mouse, each treatment formulation being injected into 8 mice. The footpad thickness of each mouse of each of the treatment groups was measured, and the results are shown in Fig. 15A.

As seen in the figure, the control mice (open circles),  
10 that is the mice injected with tumor cells not treated with doxorubicin, had a continual increase in footpad thickness after injection of the tumor cells. Mice receiving cells treated with free doxorubicin (closed circles) and mice receiving tumor cells treated with liposome-entrapped doxorubicin (open squares) also  
15 experienced an increase in footpad thickness. Only the mice injected with cells treated with the folate-targeted liposomes (closed triangles) had no increase in footpad thickness.

At the end of the study on day 34 after injection of the treated tumor cells, the weight of each tumor-bearing mouse  
20 footpad was determined and subtracted from the average weight of a mouse footpad to determine the tumor weight in each mouse footpad. Fig. 15B shows the footpad tumor weight in grams for each of the treatment regimens. As seen, the tumors in the mice receiving the cells treated with the folate-targeted  
25 doxorubicin-entrapped liposomes (closed triangles) had the smallest average tumor weight.

Table 5 summarizes the tumor incidence and the media tumor weight for each of the treatment groups.

**Table 5**

Treatment	Final Tumor Incidence <sup>a</sup> (%)	Median Tumor weight (range) (mg)
Untreated	13/20 (65%)	381 (48-825)
Free DOX <sup>a</sup>	8/19 (42%)	239 (32-683)
DOXIL <sup>®</sup> , <sup>b</sup>	10/19 (53%)	397 (13-512)
folate-lipo-DOX	2/20 (10%)	57 (27-87)

<sup>a</sup>DOX=doxorubicin<sup>b</sup>Results of two experiments<sup>c</sup>Fisher's exact test: folate-targeted-DOX vs. Untreated, p=0.0008; folate-targeted-DOX vs. DOXIL, p=0.0057; folate-targeted-DOX vs. Free DOX, p=0.0310. All other comparisons, not significant.

The results in Table 5 point to a statistically significant decrease of the number of tumor occurrences in mice injected with tumor cells exposed to folate-targeted liposomal doxorubicin, as compared to free doxorubicin, DOXIL, and control, after 5 weeks follow-up. Tumor weights were also smaller for the folate-targeted liposomal group.

In a similar study, tumor cells treated with each of the formulation were injected subcutaneously into mice and the number of palpable tumors as a function of time after injection was determined. The results are shown in Fig. 16, and the control mice (open circles) had the highest number of tumors. The mice receiving the free doxorubicin treated cells (closed circles), after a slow initial tumor growth phase, also had a significant number of tumors after about day 20. The mice receiving the liposome formulations (open squares for non-targeted liposomes and closed triangles for folate-targeted liposomes) had the fewest tumors, with the folate-targeted liposome doxorubicin resulting in the fewest number of tumors.

### III. Examples

The following examples illustrate methods of preparing and characterizing the liposome composition of the invention and in no way are intended to be limiting.

**Example 1**  
**Preparation and Characterization of Folic Acid-PEG-DSPE**  
**Conjugates**

**A. Synthesis of Conjugate**

5 Folic acid (Fluka, 100 mg, 0.244 mmol) was dissolved in DMSO (4mL). Amino-PEG<sub>2000</sub>-DSPE (prepared as set forth in Zalipsky, S. et al., *FEBS Lett.* 353:71-74 (1994)) (400 mg, 0.14 mmol) and pyridine (2 mL) were added to the folic acid-DMSO solution followed by dicyclohexylcarbodiimide (130 mg, 0.63 mmol). The reaction was continued at room temperature for 4 hours. TLC on silica gel GF (chloroform/methanol/water 75:36:6) showed a new spot ( $R_f=0.57$ ) due to the formation of the product. Disappearance of amino-PEG-DSPE ( $R_f=0.76$ ) from the reaction mixture was confirmed by ninhydrin spray.

15 Pyridine was removed by rotary evaporation. Water (50 mL) was added to the reaction mixture. The solution was centrifuged to remove trace insolubles. The supernatant was dialyzed in Spectra/Por CE (Spectrum, Houston, TX) tubing (MWCO 300,000) against saline (50 mM, 2 x 2000 mL and water (3 x 2000 mL).

20 The resulting solution, containing only the product (single spot by TLC) was lyophilized and the residue dried *in vacuo* over P<sub>2</sub>O<sub>5</sub>. Yield: 400 mg, 90%. The synthesis is illustrated in Fig. 1.

The same protocol was used to prepare folic acid-PEG-DSPE from H<sub>2</sub>N-PEG<sub>3350</sub>-DSPE. In a similar procedure folic acid was attached to mPEG<sub>2000</sub>-NH<sub>2</sub> (Zalipsky, S., et al., *Eur. Polym. J.*, 19:1177-1183 (1983)). The product, mPEG-folic acid, was purified on silica gel (70-200 mesh, 60 Å) column using stepwise gradient of methanol (10 - 80%) in chloroform and then chloroform / methanol / water (65 : 30 : 5) for the elution of the pure product.

**B. Characterization of the Conjugate by UV Analysis**

35 Folate content value was determined by quantitative UV spectrophotometry of the conjugates in methanol (0.05 mg/mL) using folic acid extinction coefficient  $\epsilon = 27,500 \text{ M}^{-1} \cdot \text{cm}^{-1}$  at  $\lambda_{\text{max}} = 285 \text{ nm}$ . The following folic acid content values were calculated: 0.29 mmol / g (94% of theoretical value,

0.31mmol/g) for folic acid-PEG<sub>2000</sub>-DSPE; 0.21 mmol/g (97% of theoretical value, 0.22 mmol/g) for folic acid-PEG<sub>3350</sub>-DSPE, and 0.40 mmol/g (98% of the theoretical value, 0.41 mmol/g) for mPEG<sub>2000</sub>-folic acid.

C. Characterization of the Conjugate by <sup>1</sup>H-NMR (360 MHz, DMSO-D<sub>6</sub> / CF<sub>3</sub>CO<sub>2</sub>D, ~10/1 v/v)

For folic acid-PEG-DSPE: δ 0.84 (t, CH<sub>3</sub>, 6H); 1.22 (s, CH<sub>2</sub>, 56H); 1.49 (m, CH<sub>2</sub>CH<sub>2</sub>CO, 4H); 2.1-2.3 (overlapping 2 x t, CH<sub>2</sub>CH<sub>2</sub>CO & m, CH<sub>2</sub> of Glu, 8H); 3.2 (m, CH<sub>2</sub>CH<sub>2</sub>N, 4H); 3.50 (s, PEG, ~180H and ~300H for derivatives of PEG2000, and ~3350 respectively); 4.02 (t, CH<sub>2</sub>OCONH, 2H); 4.1 (dd, trans-PO<sub>4</sub>CH<sub>2</sub>CH, 1H); 4.3 (dd, cis-PO<sub>4</sub>CH<sub>2</sub>CH, 1H); 4.37 (m, α-CH, 1H); 4.60 (d, 9-CH<sub>2</sub>-N, 2H); 5.15 (M, PO<sub>4</sub>CH<sub>2</sub>CH, 1H); 6.65 (d, 3',5'-H,2H); 7.65 (d, 2',6'-H); 8.77 (s, C7-H, 1H) ppm. For mPEG-folic acid: δ 1.85-2.1 (m, β-CH<sub>2</sub> of Glu, 2H); 2.3 (m, γ-CH<sub>2</sub> of Glu, 2H); 3.11 (m, CH<sub>2</sub>CH<sub>2</sub>N,4H); 3.50 (s, PEG, ~180H); 4.3 & 4.37 (minor & major α-CH<sub>2</sub> of Glu, 1H); 4.60 (9-CH<sub>2</sub>-N, 2H); 6.65 (d, 3',5'-H, 2H); 7.66 (d, 2',6'-H,2H); 8.77 (s, C7-H, 1H) ppm.

D. Characterization of the Conjugate by Mass Spectra (MALDI-TOFMS)

The spectra were obtained by Charles Evans & Associates (Redwood City, CA) with PHI-EVANS MALDI triple electrostatic analyzer time-of-flight mass spectrometer (desorption laser: 337 nm, 600 psec pulse width), utilizing gentrinsic acid as a matrix material. The spectra exhibited a bell-shaped distributions of 44 DA-spaced lines centered at 3284 for folic acid-PEG2000-DSPE (calculated molecular weight 3200 Da); 4501 for folic acid-PEG3350-DSPE (calculated molecular weight 4540 Da); and at 2400 for mPEG-folic acid (calculated molecular weight 2423 Da).

E. HPLC monitoring of carboxypeptidase G-mediated Cleavage

A HPLC system, Shimadzu 10 A, equipped with Phenomenex Prodigy C8 (4.6.50 mm) column was used at 1 mL/min, while

monitoring  $\lambda = 285$  nm. For analysis of folic acid-PEG-DSPE the system was used in isocratic mode, methanol / 10 mM sodium phosphate, pH 7.0 (92:8, v/v). The conjugate eluted as a single peak with a retention time of 5.7 min. Analysis of mPEG-folic acid was performed by a gradient mode, using 10 mM sodium phosphate, pH 7.0 with methanol (0-35% in 25 min). The conjugate eluted as a single peak with retention time of 19.6 min. In both cases it was possible to follow the enzymatic cleavage of pterate from the folic acid-moiety of the conjugates by the decrease in the total conjugate peak area. A solution of folic acid-PEG-DSPE (0.1 mg/ml) was prepared in 150 mM Tris buffer, pH 7.3. An aliquot (10  $\mu$ L) of this solution was injected into HPLC to obtain the time zero peak integration. The enzyme carboxypeptidase G (CPG, Sigma, one unit) was added to the folic acid-PEG-DSPE solution. The resulting solution was incubated at 30 °C water bath and aliquots (10  $\mu$ L) were injected into the HPLC at different time intervals. The rate of enzymatic hydrolysis was initially rapid the slowing after 4 hours of incubation time. Additional one unit aliquots of CPG were added to the reaction mixture at 4 hours and 20 hours. Data was collected for up to 27 hours. Despite the prolonged incubation times and multiple additions of the enzyme the disappearance of the conjugate peak did not exceeded 20% of the initial integration value, indicating that 80% of the folic acid-PEG-DSPE was  $\gamma$ -carboxyl linked. The experiment performed with mPEG-folic acid as a substrate showed that this conjugate contained ~90% of folic acid residues  $\gamma$ -carboxyl linked.

## Example 2

### Cell Culture and Binding Studies

#### A. Cell Culture

Cells were cultured in normal or folic acid-free RPMI medium, with 10% fetal bovine serum, glutamine 2mM, penicillin 50 u/mL, and streptomycin 50  $\mu$ g/mL. The concentration of folic acid in the serum-containing folic acid-free medium is only 3 nM, as opposed to 2.26  $\mu$ M (1 mg/L) under normal culture conditions. Cells were routinely passed by treatment with

trypsin (0.05%) - EDTA (0.02%) solution in Industries (Beyt Haernek, Israel), and fetal bovine serum was from GIBCO (Grand Island, NY).

(i) **Cell lines:** M109, a murine lung carcinoma line of BALB/c mice (Marks, T.A. et al., *Cancer Treat. Rep.*, 61:1459-1470 (1997)), and a subline of these cells, M109R displaying multidrug-resistance, (approximately 100 fold increased resistance to doxorubicin) were used in most of the studies. Both cell lines express *in vitro* low amounts of folic acid receptors and are therefore referred to as M109-LoFR and M109R-LoFR. By culturing these cells in folic acid-free medium for several passages, two sublines expressing a high amount of folic acid receptors were obtained. These sublines were adapted to grow under low folic acid conditions with generation doubling times similar to the lines of origin. These sublines are referred to as M109-HiFR and M109R-HiFR, to emphasize the over-expression of folic acid receptors.

KB cells, a human nasopharyngeal epidermal carcinoma (Saikawa, Y., *Biochemistry*, 34:9951-9961 (1995)), were also grown in low folic acid medium to obtain cells over-expressing folic acid receptors, KB-HiFR cells. Other cell lines used in this study were A375, a human melanoma line, and normal human fibroblasts which were kindly provided by the Genetics Department of Hadassah Hebrew University Hospital.

#### B. Cell Binding of Free Folate, Folic Acid-PEG Conjugates and Liposomes

Binding was assayed through measurement of cell-associated liposomal  $^3\text{H}$ -Chol or  $^3\text{H}$ -folic acid. 48 hours prior to an assay,  $5 \times 10^5$  cells were seeded in a 35 mm dish, to obtain about  $10^6$  cells/plate. Plates preincubated with medium and serum for 2 days, without cells, were used as controls. For the assays, plates were washed twice with folic acid-free RPMI medium, and incubated at 37 °C with 1 mL of folic acid-free RPMI medium containing 0.1  $\mu\text{M}$  radiolabeled folic acid or liposomes in amounts of 30-300 nmoles phospholipid. After incubation, the plates were rinsed 3 times with 2 mL ice-cold PBS, and the



radiolabels were extracted with 1 mL of 0.5 N NaOH overnight, followed by neutralization with 1 mL 0.5 N HCL. To analyze radioactivity associated with cells, cells were released from plates by trypsin-EDTA treatment, washed 3 times with PBS, and then extracted following the same procedure. Radioactivity was determined by liquid scintillation counting. Based on the specific ratio of cpm/phospholipid for each liposome formulation, the results were translated into picomoles phospholipid per million cells.

For acid wash treatment following binding, each dish was washed twice with acidified saline (pH=3), followed by wash with PBS, and then extracted as described above.

For treatment of cells with phosphatidylinositol-phospholipase C (PI-PLC), M109 HiFR cells were rinsed twice with folate-free RPMI medium were exposed to 0.1 u/mL phosphoinositol phospholipase-C (PI-PLC) (Boehringer, Mannheim) in folate-free RPMI medium for 60 minutes at 37°C. Subsequently, the cells were rinsed again twice with folate-free RPMI medium and exposed to folate-targeted liposomes for 1 hour at 4°C. Microscopic examination was done with fixed cell samples.

In studies performed with cells in suspension, cells from monolayers were released by trypsin - EDTA treatment, followed by three washes (7 min, 500g centrifugation) in folic acid-free RPMI medium. The suspended cells ( $1-10 \times 10^6$  cells/mL) were incubated with radiolabeled free folic acid or liposomes (concentration as indicated for each study) for 30 min in 5-mL plastic tubes. Unbound material was removed by four washes with PBS.

### Example 3

#### Liposome Preparation

Liposomes composed of hydrogenated soybean phosphatidylcholine (HSPC) (Avanti Polar Lipids, Birmingham, AL), cholesterol (Chol) (Sigma, St. Louis, MO) and methoxyPEG<sub>2000</sub>-DSPE (mPEG-DSPE) were prepared as described previously (Zalipsky, S., et al, *Bioconjugate Chem.*, 4:296-299 (1993)). The liposome compositions are set forth in Table 2,

above and, as discussed, because all of the formulations contained HSFC, Chol, and DSPE, thus, they are referred to herein according to folic acid-PEG/mPEG content. Fig. 3 schematically illustrates the formulations.

5 All liposome preparations were spiked with a trace amount of  $^3\text{H}$ -Cholhexadecyl ether (NEN, Boston, MA). Liposomes were made by hydration at 55-60 °C of either a thin dry lipid film obtained by rotary evaporation of a chloroform:methanol (1:1) lipid solution or a freeze-dried lipid "cake" obtained by  
10 lyophilization of *tert*-butanol lipid solution. The buffer used was 5% dextrose/15 mM Hepes, pH 7.4 at a concentration of 50-100  $\mu\text{moles}$  phospholipid/mL. Hydration was followed by high-pressure extrusion through double-stacked polycarbonate membranes with pore sizes from 1.0 to 0.05  $\mu\text{m}$  using a stainless  
15 steel device from Lipex Biomembranes (Vancouver, BC). Liposomes were sterilized by filtration through 0.22  $\mu\text{m}$  cellulose membranes. Liposome characterization included: phospholipid concentration based on phosphorus content, folic acid concentration based on the UV absorbance of folic acid at  
20 285 nm after liposome disruption in sodium dodecyl sulfate solution (10%), vesicle size as determined by dynamic laser scattering, and, in some preparations, free fatty acid content to check for phospholipid hydrolysis. All liposome  
25 preparations had a mean vesicle size between 70-90 nm with a standard deviation <25% and a unimodal size distribution. Phospholipid hydrolysis was not detected in the preparations tested here.

30 **Example 4**  
**Binding and Internalization of Folate-targeted Liposomes to**  
**M109 HiFR Cells**

A. Liposome Preparation

Liposomes were prepared according to the procedure of Example 3 to include DPPE-rhodamine (Avanti Polar Lipids,  
35 Birmingham, AL) as follows:

Formulation	Liposome Component Molar Percent				
	HSFC	Chol	DSPE- PEG <sub>2000</sub> - Folate	mPEG- DSPE <sub>2000</sub>	DPPE- rhodamine
Rh <sup>1</sup> -folic acid-PEG <sub>2000</sub>	98.9	70	1.0	0	0.1
Rh-folic acid- PEG <sub>2000</sub> /mPEG	91.9	70	1.0	7	0.1

<sup>1</sup>Rh=rhodamine

### B. Confocal Microscopy

M109 HiFR cells were plated, 24 hours prior to each study, on 24 mm cover slips inserted into 35mm culture dishes. Exposure times of the cells to the liposome composition or to free doxorubicin are indicated for each study. Cells were fixed with the buffered, PBS solution containing 4% formalin /1.5% methanol (Bio-Labs, Israel) at 4°C for 15 minutes, then washed 4 times with PBS (Gibco, Grand Island, NY). Next, the cover slips were put on slides coated with buffered mounting medium consisting of 90% glycerol/10% PBS/0.1% NaN<sub>3</sub> and 3% DABCO (Sigma) as anti-fading agent.

Microscopic visualization of live (non fixed) cells was done in PBS containing 2mM MgSO<sub>4</sub>/1mM HEPES (Sigma), pH 7.5.

Examination of the cells was done with inverted Zeiss confocal laser scanning microscope (LSM410) (Carl Zeiss, Jena, Germany). Maximum excitation was done by 543nm line of the internal He-neon laser; fluorescence emission was observed above 570nm with long-pass barrier filter LP-570) for rhodamine. For doxorubicin, maximum excitation was done by 488nm line of internal Argon laser: fluorescence emission was observed above 515nm with long pass barrier filter LP-515. A water immersion objective C-Apochromat 63x1.2 W corr. (Zeiss) was used. Images were converted to TIF file format, and the contrast level and brightness of the images were adjusted by using the Zeiss LSM410 program. The images were printed from QMS magicolor 2 printer at 1200 dpi.

**Example 5****Preparation of Doxorubicin Liposomes and In vitro Binding****A. Liposome Preparation**

Preparation of liposomes was carried out as described by Gabizon (*J. Drug Targeting*, 3:391-398, (1996), and were composed of hydrogenated soybean phosphatidylcholine (HSPC, Avanti Polar Lipids, Birmingham LA, USA), cholesterol (Sigma), DSPE-PEG-Folate. The doxorubicin to phospholipid ratio was between 110-150  $\mu\text{g}/\mu\text{mol}$ . Doxorubicin-loaded liposomes lacking the folate targeting ligand, but having a surface coating of PEG, were as described in Cabanes, A., et al., *Clinical Cancer Res.* 4:499-505, (1998), and as sold under the tradename DOXIL (Sequus Pharmaceuticals, Inc.).

**B. In vitro Binding**

M109R-HiFR cells were incubated with free doxorubicin or with doxorubicin entrapped in folate-targeted liposomes at a doxorubicin concentration of  $4 \times 10^{-5}$  M. The doxorubicin molecule was tracked using fluorescence.

**Example 6****Verapamil Blockade of Efflux Pump and Delivery of Doxorubicin**

Monolayers of M109R HiFR cells in 35mm culture dishes were exposed to  $0.5 \times 10^{-5}$  M doxorubicin as free drug or in folate-targeted liposomes for 1 hour at 37 °C, in the presence or absence of 10  $\mu\text{mol}$  verapamil (Teva, Israel) followed by PBS washing (7 min, 500g centrifugation). Then, the washed cells were rinsed and further incubated with verapamil for 2 hours. Cells were released from monolayer with 0.05% trypsin/0.02% EDTA (Gibco, Grand Island, NY), and were split into two fractions, one fraction for cellular doxorubicin determination using fluorescence and the other fraction for flow cytometry assay. Cellular doxorubicin determination was determined by extracting the doxorubicin with 0.075N HCl/ 90% isopropyl alcohol at 4°C overnight, centrifuging and assaying the supernatant collection for doxorubicin by fluorescence using a fluorimeter (Kontron, Lumitron, Israel) at Ex 470nm; Em590nm.

The flow cytometry assay was performed as follows. Suspended M109R-HiFR cells as described above, were analyzed by flow cytometry using a FACS-Star Plus (Becton-Dickinson, Immunofluorometry System, Mountain View, CA) flow cytometer. Cells were passed at a rate of approximately 1000 cells/sec through a 70  $\mu$ m nozzle, using saline as the sheath fluid. A 488nm argon laser beam at 250mW served as the light source for excitation. Red (doxorubicin derived) fluorescence was measured using a 575nm DF 26 band-pass filter.

The results are shown in Figs. 11A-11B and in Table 4.

#### Example 7

##### Cellular and Nuclear Doxorubicin Quantitation

M109-HiFR and M109R-HiFR cells were exposed to free doxorubicin or to doxorubicin entrapped in folate-targeted liposomes for 1 hour and 4 hours. Quantitation of drug accumulating in the cells was done fluorometrically on trypsinized cells as described above in Example 6. Doxorubicin exposed M109R-HiFR cells trypsinized and PBS washed were suspended for 10min at 4°C, in the following solution: 100mM NaCl/1mM EDTA/1%Triton X-100 (Sigma)/10mM Tris (Sigma), pH 7.4, then centrifuged (15min, 800g). Cell nuclei precipitate was separated from cell cytosol and doxorubicin was extracted from both fractions as described in Example 6. The results are shown in Fig 13.

#### Example 8

##### Cytotoxicity Studies

M109 HiFR and M109R HiFR cells in folate-free RPMI medium seeded in 96 well plates (6 replicates) at a density of  $10^3$  cells/well, were exposed for 1 hour to doxorubicin in free form, in non-targeted liposome-entrapped form and in folate-targeted liposome-entrapped form. After exposure the cells were rinsed twice and incubated further for 120 hours in the above medium. Cell growth assay was done using 2.5% glutaraldehyde (Merck) as fixative, followed by methylene blue (Merck) staining, and absorbance measurements at 620nm on an automated plate reader. The results are shown in Figs. 14A-14B.

**Example 9****In vivo Adoptive Tumor Growth Assay**

Female 10-week-old BALB/c mice were maintained in a specific pathogen-free facility. M109R-HiFR cells in in vitro suspension ( $10^7$  cells/ml) were exposed to  $10^{-5}$ M doxorubicin either as free drug, as liposome-entrapped (Doxil®), or as folate-targeted liposome-entrapped for 2 hours, washed with PBS, and then resuspended at a concentration of  $2 \times 10^7$  cells. Healthy, syngeneic BALB/c mice were injected into the right hind footpad with 50  $\mu$ l ( $10^6$  cells). The footpad thickness was measured with calipers once or twice a week for 5 weeks. After 35 days, mice were sacrificed, the final number of tumors recorded, and the control and tumor-inoculated footpads were sectioned at the ankle level and weighed. Tumor weight was estimated as the difference between the weight of the normal and tumor-bearing footpad. The statistical significance of differences in the final incidence of tumors per group was analyzed by contingency tables and the Fisher's exact test. The results are shown in Figs. 15A-15B and Fig. 16 and in Table 5.

Although the invention has been described with respect to particular embodiments, it will be apparent to those skilled in the art that various changes and modifications can be made without departing from the invention.

IT IS CLAIMED:

1. A method of administering a therapeutic compound to a cell expressing P-glycoprotein, comprising

5 preparing a conjugate composed of (i) a carrier; (ii) a folate ligand attached to the carrier; and (iii) a therapeutic agent associated with the carrier; and

administering the conjugate to a subject.

10 2. The method of claim 1, wherein said preparing includes preparing a conjugate where the carrier is a natural or synthetic polymer.

15 3. The method of claim 1, wherein said preparing includes preparing a conjugate where the carrier is a protein or peptide macromolecule.

20 4. The method of claim 1, wherein said preparing includes preparing a conjugate where the carrier is a liposome having a surface coating of hydrophilic polymer chains and the folate ligand is attached to a distal end of the polymer chains.

25 5. The method of claim 4, wherein the polymer is polyethyleneglycol having a molecular weight of at least about 3,500 Daltons.

30 6. The method of claim 1, wherein said preparing includes preparing a conjugate where the therapeutic agent is a chemotherapeutic drug.

7. The method of claim 1, wherein said preparing includes preparing a conjugate where the therapeutic agent is an anthracycline antibiotic.

35 8. The method of claim 7, wherein the anthracycline antibiotic is selected from the group consisting of doxorubicin, daunorubicin, epirubicin, idarubicin, mitoxantrone and an anthraquinone drug.

9. A method of administering to a cell a therapeutic compound which in free form does not accumulate in the cell, comprising,

preparing liposomes composed of (i) vesicle-forming lipids and including a vesicle forming lipid derivatized with a hydrophilic polymer chain having a free distal end, (ii) a folate ligand attached to the free distal end of at least a portion of the hydrophilic polymer chains, and (iii) a therapeutic agent entrapped in the liposomes; and

administering the liposomes to a subject; whereby accumulation of the compound in the cell is achieved in an amount sufficient for cell cytotoxicity.

10. The method of claim 9, wherein said preparing includes preparing liposomes where the hydrophilic polymer is polyethylene glycol having a molecular weight of at least about 3,500 Daltons.

11. The method of claim 9, wherein said preparing includes preparing liposomes where the therapeutic agent is an anthracycline antiobiotic.

12. The method of claim 11, wherein the anthracycline antiobiotic is selected from the group consisting of doxorubicin, daunorubicin, epirubicin idarubicin, mitoxantrone and an anthraquinone drug.

13. A composition for administration of a therapeutic compound to a multi-drug resistant cell in a person suffering from cancer, comprising a carrier molecule; at least one folate ligand attached to the carrier molecule; and

a therapeutic compound associated with the carrier, wherein said composition is effective to achieve accumulation of the therapeutic compound in the cell in an amount sufficient to be cytotoxic.



14. The composition of claim 13, wherein the carrier is a natural or synthetic polymer.

15. The composition of claim 13, wherein the carrier is a protein or peptide macromolecule.

16. The composition of claim 13, wherein the carrier is a liposome having a surface coating of hydrophilic polymer chains and the folate ligand is attached to a distal end of the polymer chains.

17. The composition of claim 16, wherein the hydrophilic polymer is polyethylene glycol having a molecular weight of at least about 3,500 Daltons.

18. A liposome composition for administration of a therapeutic compound to a multi-drug resistant cell in a person suffering from cancer, comprising

liposomes composed of vesicle-forming lipids and including a vesicle forming lipid derivatized with a hydrophilic polymer chain having a free distal end,

a folate ligand attached to the free distal end of at least a portion of the hydrophilic polymer chains, and

a therapeutic agent entrapped in the liposomes, wherein said composition is effective to achieve accumulation of the therapeutic compound in the cell in an amount sufficient to be cytotoxic.


19. The composition of claim 14, wherein the hydrophilic polymer is polyethylene glycol having a molecular weight of at least about 3,500 Daltons.

20. The composition of claim 18, wherein the therapeutic agent is an anthracycline antibiotic.


21. The composition of claim 20, wherein the anthracycline antibiotic is selected from the group consisting of doxorubicin, daunorubicin, epirubicin idarubicin, mitoxantrone and an anthraquinone drug.


ABSTRACT

5 A composition for administration of a therapeutic compound  
to a multi-drug resistant cell in a person suffering from a  
drug-resistant cancer is described. The composition is  
composed of a carrier molecule and a folate targeting ligand,  
which is covalently attached to the carrier, and the  
therapeutic compound. In one preferred embodiment, the carrier  
is a liposome having a surface coating of hydrophilic polymer  
10 chains where a folate ligand is attached to the free distal end  
of at least a portion of the hydrophilic polymer chains, and  
the therapeutic agent is entrapped in the liposomes. The  
composition is effective to achieve accumulation of the  
therapeutic compound in the cell in an amount sufficient to be  
15 cytotoxic. Also described are methods for administering a  
therapeutic compound to a person suffering from a multi-drug  
resistant condition.




**Fig. 1**

**Fig. 2**




Low mPEG2000

**Fig. 3A**




FA-PEG2000

**Fig. 3B**




FA-PEG3350

**Fig. 3C**




High mPEG2000

**Fig. 3D**




FA-PEG2000/mPEG

**Fig. 3E**




FA-PEG3350/mPEG

**Fig. 3F**



**Fig. 4A**



**Fig. 4B**

Fig. 5A



Fig. 5B



Fig. 5C




Fig. 5D



09467413.121799  
667121.61429460

**Fig. 6A**




**Fig. 6B**






**Fig. 7A**




**Fig. 7B**




**Fig. 8A**

**Fig. 8B**




**Fig. 9A**

**Fig. 9B**



**Fig. 9C**

**Fig. 9D**




**Fig. 9E**

**Fig. 9F**


09467413.121799  
667121\*EF479460




**Fig. 10A**



**Fig. 10B**



**Fig. 10C**



**Fig. 10D**




Fig. 11A







Fig. 11B




**Fig. 12**




**Fig. 13**




**Fig. 14A**



**Fig. 14B**




**Fig. 15A**



**Fig. 15B**





**Fig. 16**

**INVENTORSHIP DECLARATION BY JOINT INVENTORS**

I HEREBY DECLARE THAT:

My residence, post office address, and citizenship are stated next to my name in PART A on hereof.

I believe I am the original, first, and joint inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled

**METHOD OF ADMINISTERING A COMPOUND TO MULTI-DRUG RESISTANT CELLS**

the specification of which:

- ☒ is attached hereto.
- ☐ was filed on \_\_\_\_\_ as Application Serial No. \_\_\_\_\_ and was amended on \_\_\_\_\_ (if applicable).

I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56.

I hereby claim priority benefits under Title 35, United States Code §119 of any foreign application(s) for patent or inventor's certificate listed in PART B hereof and have also identified in PART B on hereof any foreign application for patent or inventor's certificate having a filing date before that of the application of which priority is claimed.

I hereby claim the benefit under Title 35, United States Code §119(e) and §120, of any United States application(s) listed in PART C hereof and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of the first paragraph of Title 35, United States Code §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations §1.56 which occurred between the filing date of the prior application and any national or PCT international filing date of this application.

I hereby declare that all statements made herein of my knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Please direct all telephone calls to Judy M. Mohr at (650) 324-0880. Address all correspondence to:

**Dehlinger & Associates  
P.O. Box 60850  
Palo Alto, CA 94306-0850**

INVENTORSHIP DECLARATION BY JOINT INVENTORS

**PART A: INVENTOR INFORMATION AND SIGNATURE**

Full name of FIRST inventor: Alberto A. Gabizon

Citizenship: Israel Post Office Address: Peretz Bernstein Street 56  
Jerusalem 96920, Israel

Residence (if different):

Inventor's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Full name of SECOND inventor: Samuel Zalipsky

Citizenship: U.S.A. Post Office Address: 1202 Truman Street  
Redwood City, CA 94061

Residence (if different):

Inventor's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Full name of THIRD inventor: Dorit Goren-Rubel

Citizenship: Israel Post Office Address: Bevt Arava Street 22  
Jerusalem 93389, Israel

Residence (if different):

Inventor's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Full name of FOURTH inventor: Aviva T. Horowitz

Citizenship: Israel Post Office Address: Nili Street 8  
Jerusalem 92548, Israel

Residence (if different):

Inventor's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

0045743-137789  
004421-ETH2560

**INVENTORSHIP DECLARATION BY JOINT INVENTORS**

**PART B: CLAIM TO PRIORITY OF FOREIGN APPLICATION(S) UNDER 35 U.S.C. 119(a-d)**

Country	App. No.	Filing Date
---------	----------	-------------

**PART C: CLAIM TO PRIORITY OF U.S. PROVISIONAL AND NONPROVISIONAL APPLICATION(S) UNDER 35 U.S.C. 119(e) AND 120**

Serial No.	Filing Date	Status
<u>60/113,004</u>	<u>18 December 1998</u>	<input type="checkbox"/> Patented <input checked="" type="checkbox"/> Pending <input type="checkbox"/> Abandoned

60/113,004